Zdrowie i gospodarka · 15/01/2021

Patient-Focused Drug Development for Vitiligo; Public Meeting; Request for Comments

In the Federal Register notice published on March 19, 2020, the Food and Drug Administration (FDA, Agency, or we) announced the cancellation of the public meeting entitled "Patient-Focused Drug Development for Vitiligo" originally scheduled to occur on March 30, 2020, as announced in the Federal Register on February 12, 2020. FDA is announcing a new date for the meeting, to occur in a virtual format. The purpose of the public meeting is to allow FDA to obtain patient perspectives on the impact of vitiligo on daily life, patient views on treatment approaches, and decision factors considered when selecting a treatment.